News

Video

Overcoming Barriers to Triplet Therapy in Prostate Cancer

Author(s):

David Morris, MD, FACS,Benjamin Garmezy, MD

Join experts David Morris, MD, FACS, and Benjamin Garmezy, MD, as they discuss the barriers and considerations in prescribing triplet therapy, offering insight into its benefits and how collaborative care between urologists and medical oncologists ensures a seamless patient journey.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

      Subscribe Now!
      Related Videos
      Christine Ibilibor, MD, highlights study of racial differences in abiraterone use
      Christine Ibilibor, MD, highlights study of racial differences in abiraterone use
      Laura Davis, MD, on persistent poverty and early onset prostate cancer
      Laura Davis, MD, on persistent poverty and early onset prostate cancer
      Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
      Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
      Ruben Olivares, MD, answers a question during a Zoom video interview
      Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
      Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
      Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
      Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
      Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
      Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
      Post-RP incontinence: Low procedure rates examined
      Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
      Data link incontinence severity to post-radical prostatectomy care
      Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
      Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
      Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
      Expert discusses differentiating prostate cancer from age-related issues
      Related Content
      Irreversible electroporation with NanoKnife found safe, effective for prostate tissue ablation
      July 22nd 2025

      Irreversible electroporation with NanoKnife found safe, effective for prostate tissue ablation

      Hannah Clarke
      The PRESERVE trial met its primary end point by demonstrating a negative in-field biopsy rate of 71% at 12 months.
      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
      April 27th 2025

      Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

      Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
      Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
      Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
      July 18th 2025

      Phase 3 TALAPRO-2 data of talazoparib plus enzalutamide published in The Lancet

      Hannah Clarke
      In both cohorts, the combination of talazoparib plus enzalutamide led to a significant improvement in overall survival vs enzalutamide alone.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      CMS issues reimbursement code for PSMA-PET imaging agent Gozellix
      July 15th 2025

      CMS issues reimbursement code for PSMA-PET imaging agent Gozellix

      Hannah Clarke
      The level II code A9616 will be effective starting on October 1, 2025.
      Carotuximab plus apalutamide demonstrates safety, tolerability in mCRPC
      July 15th 2025

      Carotuximab plus apalutamide demonstrates safety, tolerability in mCRPC

      Hannah Clarke
      The company said it plans to report interim efficacy data from the trial in September 2025.
      © 2025 MJH Life Sciences

      All rights reserved.